Diabetes Care· 2022Q1· Guideline
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- 1,982citations
- Q1SCImago
- 2022year
Short summary
New ADA/EASD guidelines emphasize social determinants of health, weight management, and cardiorenal protection with SGLT2 inhibitors and GLP-1 RAs for type 2 diabetes.
AI-generated from the title and abstract; the full text is not read.
Key points
- Updated consensus on hyperglycemia management in type 2 diabetes by ADA and EASD.
- Incorporates new evidence from publications since 2018.
- Increased emphasis on social determinants of health, weight management, and physical activity.
- Expanded recommendations for cardiorenal protection using SGLT2 inhibitors and GLP-1 RAs.
AI-generated from the title and abstract; the full text is not read.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
The authors' abstract, as published at the source. Diabetes Care, 2022 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine